AC430   Click here for help

GtoPdb Ligand ID: 9177

Synonyms: AC-430
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: AC430 is an investigational, potent and selective small molecule inhibitor of janus kinase 2 (JAK2) being developed by Ambit (now owned by Daiichi Sankyo) for the treatment of cancer and autoimmune diseases. AC430 is the (R) optical isomer claimed in patent US8703943 [1], although the (S) isomer and racemate are also discussed in the patent descriptions.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 3
Rotatable bonds 4
Topological polar surface area 86.72
Molecular weight 349.13
XLogP 3.37
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES Fc1ccc(cc1)C(c1nc(Nc2n[nH]c(c2)C)c2c(n1)cccc2)O
Isomeric SMILES Fc1ccc(cc1)[C@H](c1nc(Nc2n[nH]c(c2)C)c2c(n1)cccc2)O
InChI InChI=1S/C19H16FN5O/c1-11-10-16(25-24-11)22-18-14-4-2-3-5-15(14)21-19(23-18)17(26)12-6-8-13(20)9-7-12/h2-10,17,26H,1H3,(H2,21,22,23,24,25)/t17-/m1/s1
Bioactivity Comments
Patent US8703943 [1] does not provide inhibitory constants for the compounds vs. janus kinase enzymes. It also suggests that AC430 acts as an antagonist of the adenosine A3 receptor with an IC50 value of 28nM (Ki 26nM).
Selectivity at enzymes
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
Janus kinase 2 Hs Inhibitor Inhibition - - - 1